Conducting clinical trials during the COVID-19 pandemic-a collaborative trial network response.

Autor: Robison L; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia. l.robison@uq.edu.au., Cho Y; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.; The Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia., Viecelli AK; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.; The Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia., Johnson DW; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.; The Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.; The Translational Research Institute, Brisbane, QLD, Australia., Hawley CM; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.; The Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.; The Translational Research Institute, Brisbane, QLD, Australia., Valks A; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia., Paul-Brent PA; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia., Stastny R; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia., Varghese J; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia., Kiriwandeniya C; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia., Pascoe EM; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia., Vergara LA; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia., Fahim MA; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.; The Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.; Metro North Hospital & Health Service, Brisbane, QLD, Australia., Boudville N; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.; The Medical School, University of Western Australia, Perth, WA, Australia., Krishnasamy R; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.; Department of Nephrology, Sunshine Coast University Hospital, Birtinya, QLD, Australia., Reidlinger D; Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Jazyk: angličtina
Zdroj: Trials [Trials] 2021 Apr 14; Vol. 22 (1), pp. 278. Date of Electronic Publication: 2021 Apr 14.
DOI: 10.1186/s13063-021-05200-0
Abstrakt: The unprecedented demand placed on healthcare systems from the COVID-19 pandemic has forced a reassessment of clinical trial conduct and feasibility. Consequently, the Australasian Kidney Trials Network (AKTN), an established collaborative research group known for conducting investigator-initiated global clinical trials, had to efficiently respond and adapt to the changing landscape during COVID-19. Key priorities included ensuring patient and staff safety, trial integrity and network sustainability for the kidney care community. New resources have been developed to enable a structured review and contingency plan of trial activities during the pandemic and beyond.
Databáze: MEDLINE